The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer

T

Tianjin Medical University

Status

Enrolling

Conditions

Chemotherapy
Pancreas Cancer

Treatments

Other: Adjuvant chemotherapy

Study type

Observational

Funder types

Other

Identifiers

NCT06208436
Adchmopan01

Details and patient eligibility

About

This study aimed to evaluate the impact of adjuvant chemotherapy on survival in patients with Stage I pancreatic cancer stratified by pathologic risk factors.

Enrollment

250 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: Patients who underwent surgical resection and were pathologically diagnosed as PDAC between 2010 and 2021.

Exclusion Criteria: Patients with pN1-N2, patients with pT3-T4, patients with distant metastasis, patients who received neoadjuvant therapy, patients with R1 resection, and patients who died due to perioperative mortality within 30 days.

Trial design

250 participants in 1 patient group

TMUCIH-PDAC
Description:
Between 2010 and 2021, the data of patients who underwent surgical resection and were pathologically diagnosed as PDAC from Tianjin Medical University Cancer Institute and Hospital (TMUCIH) were collected retrospectively.
Treatment:
Other: Adjuvant chemotherapy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems